1 Introduction
Nasopharyngeal carcinoma (NPC) is a malignant neoplasm with high radiosensitivity that has a unique etiology and geographic distribution. Due to the special anatomical location of the tumor, approximately 70% of newly diagnosed NPC cases are classified as locoregionally advanced disease, namely locally advanced nasopharyngeal carcinoma (LANC). NPC lesions often infiltrate the surrounding area, such as parapharyngeal space and internal carotid artery[1-2]. Concurrent chemoradiotherapy (CCRT), with epidermal growth factor receptor (EGFR) inhibitors, is an effective treatment option for LANC[3].